Stock of the day: Nanosonics
Nanosonics has secured FDA clearance for the CORIS system, strengthening its position in the medtech sector and driving share price growth.
(AI video summary)
This video was created on 20 March for IG audiences by ausbiz.
ASX code: NAN
FDA clearance boosts Nanosonics' medtech credibility
Nanosonics has gained attention with United States (US) Food and Drug Administration (FDA) De Novo clearance for its latest medical technology (medtech) innovation, the CORIS system. This advanced cleaning solution addresses a critical challenge in medical device reprocessing: cleaning flexible endoscopes. The FDA approval enhances Nanosonics' credibility in the medtech sector, allowing it to market the CORIS system without further approvals.
Financial gains and market response
The FDA approval has bolstered Nanosonics' financial performance, resulting in a 14% increase in its share price. Management recently upgraded its financial year (FY) 2025 guidance, citing strong sales growth and the favourable impact of a lower Australian dollar.
Investment outlook
For traders, the FDA approval offers growth potential, but caution is advised. While the approval provides market expansion opportunities, concerns about return on capital and earnings per share (EPS) instability persist. Investors should monitor Nanosonics' ability to leverage the CORIS system's success into improved financial metrics.
News and trade ideas
Gold
-
Gold price at new record while WTI crude price slumps
The price of gold has made new highs, but crude oil prices are under pressure after a slump yesterday.Commodities -
-
-
The information on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG Bank S.A. accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer.
Explore the markets with our free course
Learn how shares work – and discover the wide range of markets you can trade CDFs on – with IG Academy's free ’introducing the financial markets’ course.
Put learning into action
Try out what you’ve learned in this shares strategy article risk-free in your demo account.
Ready to trade shares?
Put the lessons in this article to use in a live account – upgrading is quick and easy.
- Trade over 12 000 popular global stocks
- Protect your capital with risk management tools
- React to breaking news with out-of-hours trading on 70 key US stocks
Inspired to trade?
Put your new knowledge into practice. Log in to your account now.
Live prices on most popular markets
- Forex
- Shares
- Indices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.
